Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beswick

Showing results (621-630 of 673) with videos related to

Pageof 68
Sort By:
Gut|August 15, 2019
Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?Mayur Garg, Simon G Royce, Chris Tikellis, et al.
Bioorganic & Medicinal Chemistry Letters|June 16, 2009
Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approachPaul J Beswick, Andrew P Blackaby, Chas Bountra, et al.
Journal of Neurology|December 14, 2022
Genotype-phenotype characterisation of long survivors with motor neuron disease in ScotlandDanielle J Leighton, Morad Ansari, Judith Newton, et al.
Journal of Medicinal Chemistry|October 6, 2025
High-Throughput Identification and Characterization of LptDE-Binding Bicycle Peptides Using Phage Display and Cryo-EMShenaz Allyjaun, Emily Dunbar, Steven W Hardwick, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 2, 2004
The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitizationSharon Bingham, Paul J Beswick, Chas Bountra, et al.
Trials|February 18, 2016
One-stage or two-stage revision surgery for prosthetic hip joint infection--the INFORM trial: a study protocol for a randomised controlled trialSimon Strange, Michael R Whitehouse, Andrew D Beswick, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 15, 2021
Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC studyWilliam Kemp, Ammar Majeed, Joanne Mitchell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 13, 2021
Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trialAmelia K Smit, Martin Allen, Brooke Beswick, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2009
Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR dataJuliette A Randerson-Moor, John C Taylor, Faye Elliott, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptorMuna H Abdi, Paul J Beswick, Andy Billinton, et al.
Pageof 68

Showing results (621-630 of 673) with videos related to

Sort By:
Pageof 68
Gut|August 15, 2019
Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?Mayur Garg, Simon G Royce, Chris Tikellis, et al.
Bioorganic & Medicinal Chemistry Letters|June 16, 2009
Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approachPaul J Beswick, Andrew P Blackaby, Chas Bountra, et al.
Journal of Neurology|December 14, 2022
Genotype-phenotype characterisation of long survivors with motor neuron disease in ScotlandDanielle J Leighton, Morad Ansari, Judith Newton, et al.
Journal of Medicinal Chemistry|October 6, 2025
High-Throughput Identification and Characterization of LptDE-Binding Bicycle Peptides Using Phage Display and Cryo-EMShenaz Allyjaun, Emily Dunbar, Steven W Hardwick, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 2, 2004
The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitizationSharon Bingham, Paul J Beswick, Chas Bountra, et al.
Trials|February 18, 2016
One-stage or two-stage revision surgery for prosthetic hip joint infection--the INFORM trial: a study protocol for a randomised controlled trialSimon Strange, Michael R Whitehouse, Andrew D Beswick, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 15, 2021
Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC studyWilliam Kemp, Ammar Majeed, Joanne Mitchell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 13, 2021
Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trialAmelia K Smit, Martin Allen, Brooke Beswick, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2009
Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR dataJuliette A Randerson-Moor, John C Taylor, Faye Elliott, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptorMuna H Abdi, Paul J Beswick, Andy Billinton, et al.
Pageof 68